DALLAS, Dec. 18, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Alkermes Inc. (Nasdaq:ALKS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/ALKS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Alkermes Inc. (ALKS) is an integrated biotechnology company. The Company has developed, manufactured and commercialized VIVITROL for alcohol dependence and manufactured RISPERDAL CONSTA for schizophrenia and bipolar disorder. Its pipeline includes injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. RISPERDAL CONSTA is the long-acting, atypical antipsychotic to be approved by the U.S. Food and Drug Administration (FDA). RISPERDAL CONSTA is approved for the treatment of schizophrenia in approximately 85 countries and marketed in approximately 60 countries.
Message Board Search for ALKS: http://www.boardcentral.com/boards/ALKS
In the report, the analyst notes:
"The Company is adjusting its expectation for manufacturing revenues to a range of $105 million to $111 million, revised from an expectation of $116 million to $122 million, due to changes in the purchase forecasts from Janssen. These revised expectations include manufacturing revenues related to RISPERDAL CONSTA in the range of $105 million to $110 million, revised from an expectation of $115 million to $120 million, and manufacturing revenue related to VIVITROL for the Russian market in the range of $0 to $1 million, revised from an expectation of $1 million to $2 million.
"ALKS earlier this week announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA(R) (exenatide) injection taken twice daily, in patients with type 2 diabetes."
To read the entire report visit: http://www.beaconequity.com/i/ALKS
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.